Altogether, a strong overlap of ERBB2-driven pathways was found with our homologous recombination factors, which may help define a signature to select bladder cancer patients who may benefit from targeted therapy and may use to evaluate drug response for patients. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.